A fluorescent ESIPT-based benzimidazole platform for the ratiometric two-photon imaging of ONOO- in vitro and ex vivo.
Maria L OdyniecSang-Jun ParkJordan E GardinerEmily C WebbAdam C SedgwickJuyoung YoonSteven D BullHwan Myung KimTony David JamesPublished in: Chemical science (2020)
In this work, we have developed an ESIPT-based benzimidazole platform (MO-E1 and MO-E2) for the two-photon cell imaging of ONOO- and a potential ONOO--activated theranostic scaffold (MO-E3). Each benzimidazole platform, MO-E1-3, were shown to rapidly detect ONOO- at micromolar concentrations (LoD = 0.28 μM, 6.53 μM and 0.81 μM respectively). The potential theranostic MO-E3 was shown to release the parent fluorophore and drug indomethacin in the presence of ONOO- but unfortunately did not perform well in vitro due to low solubility. Despite this, the parent scaffold MO-E2 demonstrated its effectiveness as a two-photon imaging tool for the ratiometric detection of endogenous ONOO- in RAW264.7 macrophages and rat hippocampus tissue. These results demonstrate the utility of this ESIPT benzimidazole-based platform for theranostic development and bioimaging applications.
Keyphrases
- fluorescent probe
- living cells
- molecular docking
- high resolution
- fluorescence imaging
- high throughput
- photodynamic therapy
- quantum dots
- single cell
- randomized controlled trial
- stem cells
- climate change
- emergency department
- nitric oxide
- human health
- tissue engineering
- molecular dynamics simulations
- label free
- real time pcr
- energy transfer